Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 349-355

  Asselbergs, Folkert W ^a   van der Harst, Pim ^a   van Roon, Arie M ^a   Hillege, Hans L ^a   de Jong, Paul E ^a   Gans, Reinold O B ^a   Smit, Andries J ^a   van Gilst, Wiek H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibitor; Clinical trial; Endothelium; Flow mediated vasodilation; FMD; Kidney; Microalbuminuria; Statin; Therapy

Indexed keywords

ALBUMIN; CHOLESTEROL; FOSINOPRIL; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN;

ADULT; ALBUMINURIA; ANALYTICAL ERROR; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; ULTRASOUND;

ADULT; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FOSINOPRIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRAVASTATIN; VASODILATION;

EID: 38049087013     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.11.011     Document Type: Article

References (28)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (1999) 115-126
2. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81 2 (1990) 491-497
3. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 5789 (1980) 373-376
4. Asselbergs F.W., van der H.P., Jessurun G.A., Tio R.A., and van Gilst W.H. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vascul Pharmacol 42 3 (2005) 125-140
5. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
6. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342 3 (2000) 145-153
7. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 9386 (2003) 782-788
8. Hillege H.L., Fidler V., Diercks G.F., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 14 (2002) 1777-1782
9. Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of Fosinopril and Pravastatin on cardiovascular events in microalbuminuric subjects. Circulation 110 (2004) 2809-2816
10. Diercks G.F., Stroes E.S., Boven A.J., et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. Atherosclerosis 163 1 (2002) 121-126
11. Hijmering M.L., Stroes E.S., Pasterkamp G., Sierevogel M., Banga J.D., and Rabelink T.J. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 157 2 (2001) 369-373
12. Dupuis J., Tardif J.C., Cernacek P., and Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 25 (1999) 3227-3233
13. Ohara Y., Peterson T.E., and Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91 6 (1993) 2546-2551
14. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., and Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95 1 (1997) 76-82
15. Fichtlscherer S., Rosenberger G., Walter D.H., Breuer S., Dimmeler S., and Zeiher A.M. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102 9 (2000) 1000-1006
16. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation 100 3 (1999) 230-235
17. Ling M.C., Ruddy T.D., deKemp R.A., et al. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. Am Heart J 149 6 (2005) 1137
18. Stein J.H., Merwood M.A., Bellehumeur J.L., et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 147 4 (2004) E18
19. Karatzis E., Lekakis J., Papamichael C., et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. Int J Cardiol 101 1 (2005) 65-70
20. Kayikcioglu M., Payzin S., Yavuzgil O., Kultursay H., Can L.H., and Soydan I. Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J 24 22 (2003) 1999-2005
21. Hornig B., Arakawa N., Haussmann D., and Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 98 25 (1998) 2842-2848
22. Wilmink H.W., Banga J.D., Hijmering M., Erkelens W.D., Stroes E.S., and Rabelink T.J. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 34 1 (1999) 140-145
23. McFarlane R., McCredie R.J., Bonney M.A., et al. Angiotensin converting enzyme inhibition and arterial endothelial function in adults with type 1 diabetes mellitus. Diabet Med 16 1 (1999) 62-66
24. Anderson T.J., Elstein E., Haber H., and Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 35 1 (2000) 60-66
25. Kathiresan S., Gona P., Larson M.G., et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 113 7 (2006) 938-945
26. Levenson J., Pessana F., Gariepy J., Armentano R., and Simon A. Gender differences in wall shear-mediated brachial artery vasoconstriction and vasodilation. J Am Coll Cardiol 38 6 (2001) 1668-1674
27. Kuvin J.T., Patel A.R., Sidhu M., et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol 92 3 (2003) 275-279
28. Spieker L.E., Sudano I., Hurlimann D., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 12 (2002) 1399-1402